Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Пароксизмальная ночная гемоглобинурия

Список литературы

  1. Bessler M. et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. // EMBO J. 1994. Vol. 13, № 1. P. 110–117.
  2. Takeda J. et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria // Cell. 1993. Vol. 73, № 4. P. 703–711.
  3. Medof B.Y.M.E., Kinoshita T., Nussenzweig V. INHIBITION OF COMPLEMENT OF CELLS AFTER ACTIVATION ON THE OF INCORPORATION ( DAF ) INTO THEIR MEMBRANES A key step in complement activation on targets is the deposition of C4b and / or C3b fragments . These major cleavage products of C3 and C4 can associa // J. Exp. Med. 1984. Vol. 160, № November. P. 1558–1578.
  4. Lublin D.M., Atkinson J.P. Decay-Accelerating Factor: Biochemistry, Molecular Biology, and Function // Annu. Rev. Immunol. 1989. Vol. 7, № 1. P. 35–58.
  5. Rollins S.A., Sims P.J. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. // J. Immunol. 1990. Vol. 144, № 9. P. 3478 LP – 3483.
  6. Noris M., Remuzzi G. Overview of complement activation and regulation // Semin. Nephrol. Elsevier, 2013. Vol. 33, № 6. P. 479–492.
  7. Tegla C.A. et al. Membrane attack by complement: the assembly and biology of terminal complement complexes // Immunol. Res. 2011. Vol. 51, № 1. P. 45–60.
  8. Serna M. et al. Structural basis of complement membrane attack complex formation // Nat. Commun. Nature Publishing Group, 2016. Vol. 7. P. 1–7.
  9. Sun X. et al. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting // Proc. Natl. Acad. Sci. U. S. A. 1999. Vol. 96, № 2. P. 628–633.
  10. Brodbeck W.G. et al. Structure/function studies of human decay-accelerating factor // Immunology. 2000. Vol. 101, № 1. P. 104–111.
  11. Farkas I. et al. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9 // J. Physiol. 2002. Vol. 539, № 2. P. 537–545.
  12. Bessler M., Hiken J. The pathophysiology of disease in patients with paroxysmal nocturnal hemoglobinuria. // Hematology Am. Soc. Hematol. Educ. Program. 2008. P. 104–110.
  13. Hill A., Kelly R.J., Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria // Blood. 2013. Vol. 121, № 25. P. 4985–4996.
  14. Rother R.P. et al. The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin // JAMA. 2005. Vol. 293, № 13. P. 1653.
  15. Olsen S.B. et al. Enhancement of Platelet Deposition by Cross-Linked Hemoglobin in a Rat Carotid Endarterectomy Model // Circulation. 1996. Vol. 93, № 2. P. 327–332.
  16. Simionatto C.S. et al. Thrombophlebitis and disturbed hemostasis following administration of intravenous hematin in normal volunteers // Am. J. Med. 1988. Vol. 85, № 4. P. 538–540.
  17. Studt J.-D. et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin // Blood. 2005. Vol. 105, № 2. P. 542–544.
  18. Seregina E.A. et al. Eculizumab effect on the hemostatic state in patients with paroxysmal nocturnal hemoglobinuria // Blood Cells, Mol. Dis. 2015. Vol. 54, № 2. P. 144–150.
  19. Ritis K. et al. A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation Pathways // J. Immunol. 2006. Vol. 177, № 7. P. 4794–4802.
  20. Wojta J. et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils // Blood. 2002. Vol. 100, № 2. P. 517–523.
  21. Yu F., Du Y., Han B. A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America // Int. J. Hematol. Springer Japan, 2016. Vol. 103, № 6. P. 649–654.
  22. Hill A. et al. Paroxysmal nocturnal haemoglobinuria // Nat. Rev. Dis. Prim. 2017. Vol. 3, № 1. P. 17028.
  23. Hill A. et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire. // Blood. 2006. Vol. 108, № September 2018. P. Abstract 985.
  24. Кулагин А.Д. et al. Клиническая манифестация и ошибки диагностики классической пароксизмальной ночной гемоглобинурии : анализ 150 наблюдений Clinical Manifestation and Errors in the Diagnosis of Classical Paroxysmal Nocturnal Hemoglobinuria : A case series of 150 patients. 2017. Vol. 10, № 3. P. 333–341.
  25. Hillmen P. et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria // Am. J. Hematol. 2010. Vol. 85, № 8. P. 553–559.
  26. Hill A. et al. Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: Raised pulmonary pressure and reduced right ventricular function // Br. J. Haematol. 2012. Vol. 158, № 3. P. 409–414.
  27. Sahin F. et al. Pesg PNH diagnosis , follow-up and treatment guidelines. 2016. Vol. 6, № 2. P. 19–27.
  28. Brodsky R.A. Paroxysmal nocturnal hemoglobinuria // Blood. 2014. Vol. 124, № 18. P. 2804–2811.
  29. Кулагин А.Д. et al. Национальные клинические рекомендации по диагностике и лечению пароксизмальной ночной гемоглобинурии // Онкогематология. 2014. Vol. 2. P. 20–28.
  30. Borowitz M.J. et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry // Cytom. Part B - Clin. Cytom. Wiley-Liss Inc., 2010. Vol. 78, № 4. P. 211–230.
  31. Manivannan P., Ahuja A., Pati H.P. Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances // Indian J. Hematol. Blood Transfus. Springer India, 2017. Vol. 33, № 4. P. 453–462.
  32. Movalia M.K. et al. Incidence of PNH Clones by Diagnostic Code Utilizing High Sensitivity Flow Cytometry // Blood. 2011. Vol. 118, № 21. P. 1033–1033.
  33. Sipol A.A. et al. An inter-laboratory comparison of PNH clone detection by high-sensitivity flow cytometry in a Russian cohort // Hematology. 2015. Vol. 20, № 1. P. 31–38.
  34. Dezern A.E., Borowitz M.J. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 – clinical utility // Cytom. Part B - Clin. Cytom. 2018. Vol. 94, № 1. P. 16–22.
  35. Sutherland D.R. et al. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 2 – reagent selection and assay optimization for high-sensitivity testing // Cytom. Part B - Clin. Cytom. 2018. Vol. 94, № 1. P. 23–48.
  36. Brubaker L.H., Essig L.R.J., Mengel C.E. Neutrophil life span in paroxysmal nocturnal hemoglobinuria // Blood. 1977. Vol. 50, № 4. P. 657–662.
  37. Patriquin C.J. et al. How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry // European Journal of Haematology. Blackwell Publishing Ltd, 2019. Vol. 102, № 1. P. 36–52.
  38. Бокерия Л.А., Затевахин И.И., Кириенко А.И. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). // Флебология. 2015. Vol. 4, № 2. P. 3–52.
  39. Villegas A. et al. Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria // Med. Clin. (Barc). Ediciones Doyma, S.L., 2016. Vol. 146, № 6. P. 278e1-278e7.
  40. Hill A. et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria // Blood. 2005. Vol. 106, № 7. P. 2559–2565.
  41. Hillmen P. et al. The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria // N. Engl. J. Med. 2006. Vol. 355, № 12. P. 1233–1243.
  42. Savva S. The Potential of a Museum-School Partnership to Support Diversity and Multiliteracies-Based Pedagogy for the 21st Century. 2016. Vol. 111, № 4. P. 1840–1848.
  43. Hillmen P. et al. Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria // N. Engl. J. Med. 2004. Vol. 350, № 6. P. 552–559.
  44. Reiss U.M. et al. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria // Pediatr. Blood Cancer. Pediatr Blood Cancer, 2014. Vol. 61, № 9. P. 1544–1550.
  45. McNamara L.A. et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine // MMWR. Morb. Mortal. Wkly. Rep. 2017. Vol. 66, № 27. P. 734–737.
  46. Brodsky R.A. Stem cell transplantation for paroxysmal nocturnal hemoglobinuria. 2010. Vol. 95, № 6. P. 855–856.
  47. de Latour R.P. et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria // Haematologica. 2012. Vol. 97, № 11. P. 1666–1673.
  48. SHASHELEVA D.A. et al. Hematopoietic stem cell transplantation with alpha/beta T-lymphocyte depletion and short course of eculizumab in adolescents and young adults with paroxysmal nocturnal hemoglobinuria // Ter. Arkh. 2018. Vol. 90, № 7. P. 57–64.
  49. Young N.S. et al. The Management of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances in Diagnosis and Treatment and New Hope for Patients // Semin. Hematol. W.B. Saunders, 2009. Vol. 46, № SUPPL. 1.
  50. Brecher M., Taswell H. Paroxysmal nocturnal hemoglobinuria and the transfusion of washed red cells. A myth revisited // Transfusion. 1989. Vol. 29, № 8. P. 681–685.
  51. Parker C. Diagnosis and management of paroxysmal nocturnal hemoglobinuria // Blood. 2005. Vol. 106, № 12. P. 3699–3709.
  52. Ayuk F., Balduzzi A. Donor Selection for Adults and Pediatrics // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies / ed. Carreras E. et al. Springer, 2019. P. 87–99.
  53. Carreras E., Rambaldi A. Evaluation and Counseling of Candidates // EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 77–87.
  54. Confer D.L., Miller J.P., Chell J.W. Bone Marrow and Peripheral Blood Cell Donors and Donor Registries // Thomas’ Hematopoietic Cell Transplantation. Chichester, UK: John Wiley & Sons, Ltd, 2016. Vol. 1–2. P. 423–432.
  55. Witt V., Peters C. Collection of HSC in Children // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 123–127.
  56. Gorin N.C. Bone Marrow Harvesting for HSCT // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 109–117.
  57. Hübel K. Mobilization and Collection of HSC // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 117–123.
  58. Querol S., Rocha V. Procurement and Management of Cord Blood // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 131–137.
  59. Wuchter P. Processing, Cryopreserving and Controlling the Quality of HSCs // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 127–131.
  60. Schumm M., Lang P., Handgretinger R. Graft Manipulation // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 137–143.
  61. Nagler A., Shimoni A. Conditioning // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 99–109.
  62. Danylesko I., Shimoni A., Nagler A. Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike // Bone Marrow Transplant. 2012 471. Nature Publishing Group, 2011. Vol. 47, № 1. P. 5–14.
  63. Ruutu T. How to use busulfan in conditioning for allogeneic transplantation // Cell. Ther. Transplant. Universitatsklinikum Hamburg - Eppendorf, 2018. Vol. 7, № 1. P. 18–20.
  64. Langenhorst J.B. et al. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation // Clin. Pharmacokinet. Springer, 2019. Vol. 58, № 5. P. 627.
  65. Yoshida N. et al. Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide // Bone Marrow Transplant. 2020 557. Nature Publishing Group, 2020. Vol. 55, № 7. P. 1272–1281.
  66. Penack O. et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation // The Lancet Haematology. Elsevier Ltd, 2020. Vol. 7, № 2. P. e157–e167.
  67. Michonneau D., Socié G. GVHD Prophylaxis (Immunosuppression) // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 177–183.
  68. Watanabe N. et al. Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children // Bone Marrow Transplant. 2010 457. Nature Publishing Group, 2009. Vol. 45, № 7. P. 1161–1166.
  69. Jacoby E. et al. Single agent post-transplantation cyclophosphamide as GVHD prophylaxis after HLA-matched related BMT for pediatric and young adult patients with hematologic malignancies // Biol. Blood Marrow Transplant. NIH Public Access, 2016. Vol. 22, № 1. P. 112.
  70. Baron F. et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation // Haematologica. Ferrata Storti Foundation, 2017. Vol. 102, № 2. P. 224.
  71. Koreth J. et al. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results // Haematologica. Ferrata Storti Foundation, 2018. Vol. 103, № 3. P. 522–530.
  72. Wertheimer T. et al. Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis // Ann. Hematol. 2021. Vol. 100, № 3. P. 779–787.
  73. Drobyski W.R. et al. Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease // Biol. Blood Marrow Transplant. Elsevier, 2011. Vol. 17, № 12. P. 1862–1868.
  74. Abouelnasr A. et al. Defining the Role of Sirolimus in the Management of Graft-versus-Host Disease: From Prophylaxis to Treatment // Biol. Blood Marrow Transplant. 2013. Vol. 19. P. 12–21.
  75. Schäfer H. et al. A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT // Ann. Hematol. 2021 1008. Springer, 2021. Vol. 100, № 8. P. 2095–2103.
  76. Malard F. et al. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study // Blood. Content Repository Only!, 2017. Vol. 130, № 20. P. 2186–2195.
  77. Cutler C., Antin J.H. Manifestations and Treatment of Acute Graft-versus-Host Disease // Thomas’ Hematopoietic Cell Transplantation. Chichester, UK: John Wiley & Sons, Ltd, 2016. Vol. 2–2. P. 1012–1025.
  78. Holler E., Greinix H., Zeiser R. Acute Graft-Versus-Host Disease // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 323–330.
  79. Toubai T., Magenau J. Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease // Blood. American Society of Hematology, 2020. Vol. 136, № 4. P. 429–440.
  80. Martin P.J. How I treat steroid-refractory acute graft-versus-host disease // Blood. American Society of Hematology, 2020. Vol. 135, № 19. P. 1630–1638.
  81. Nassar A. et al. Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation // J. Transplant. Hindawi Limited, 2014. Vol. 2014. P. 1–10.
  82. Kawashima N. et al. Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan // Int. J. Hematol. 2019 1094. Springer, 2019. Vol. 109, № 4. P. 491–498.
  83. Khandelwal P. et al. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients // Pediatr. Transplant. Pediatr Transplant, 2014. Vol. 18, № 1. P. 94–102.
  84. Vicent M.G. et al. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results // Am. J. Hematol. John Wiley & Sons, Ltd, 2019. Vol. 94, № 3. P. 319–326.
  85. Faraci M. et al. Etanercept as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients // Biol. Blood Marrow Transplant. Elsevier, 2019. Vol. 25, № 4. P. 743–748.
  86. Sleight B.S. et al. Infliximab for GVHD therapy in children // Bone Marrow Transplant. 2007 405. Nature Publishing Group, 2007. Vol. 40, № 5. P. 473–480.
  87. Albert M.H. et al. Oral graft vs. host disease in children - Treatment with topical tacrolimus ointment // Pediatr. Transplant. Pediatr Transplant, 2007. Vol. 11, № 3. P. 306–309.
  88. Zangrilli A. et al. Treatment of disfiguring chronic graft versus host disease in a child with topical pimecrolimus // Pediatr. Int. Pediatr Int, 2010. Vol. 52, № 3. P. e161-3.
  89. Baird K. et al. Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease // Biol. Blood Marrow Transplant. Biol Blood Marrow Transplant, 2015. Vol. 21, № 6. P. 1083–1090.
  90. Wolff D., Lawitschka A. Chronic Graft-Versus-Host Disease // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 331–347.
  91. Filipovich A.H. et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report // Biology of Blood and Marrow Transplantation. Biol Blood Marrow Transplant, 2005. Vol. 11, № 12. P. 945–956.
  92. Jagasia M.H. et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report // Biol. Blood Marrow Transplant. Elsevier Inc., 2015. Vol. 21, № 3. P. 389-401.e1.
  93. Mikulska M. Infection Control and Isolation Procedures // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 189–197.
  94. Mikulska M. Neutropenic Fever // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 259–265.
  95. Ljungman P., Styczynski J., Einsele H. Viral Infections // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 281–291.
  96. Maertens J.A. Invasive Fungal Infections // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 273–281.
  97. Groll A.H. et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation // The Lancet Oncology. Lancet Publishing Group, 2014. Vol. 15, № 8.
  98. Cesaro S. Haemorrhagic Cystitis and Renal Dysfunction // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 387–393.
  99. Carreras E., Diaz-Ricart M. Early Complications of Endothelial Origin // EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 315–323.
  100. Mahadeo K.M. et al. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement // The Lancet Haematology. Elsevier Ltd, 2020. Vol. 7, № 1. P. e61–e72.
  101. Sung L. et al. Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation // BMJ Supportive and Palliative Care. BMJ Publishing Group, 2017. Vol. 7, № 1. P. 7–16.
  102. Ghali M.G.Z. et al. Posterior reversible encephalopathy syndrome in pediatric patients: pathophysiology, diagnosis, and management // Leukemia and Lymphoma. Taylor and Francis Ltd, 2019. Vol. 60, № 10. P. 2365–2372.
  103. Cooke K.R. Acute lung injury after allogeneic stem cell transplantation: From the clinic, to the bench and back again // Pediatr. Transplant. John Wiley & Sons, Ltd, 2005. Vol. 9, № SUPPL. 7. P. 25–36.
  104. Jodele S. et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy // Transfusion and Apheresis Science. Elsevier Ltd, 2016. Vol. 54, № 2. P. 181–190.
  105. Baumgartner A., Schuetz P. Nutritional Support // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 171–177.
  106. Schrezenmeier H. et al. Transfusion Support // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 163–171.
  107. Bahar B., Tormey C.A. Prevention of transfusion-associated graft-versus-host disease with blood product irradiation the past, present, and future // Archives of Pathology and Laboratory Medicine. College of American Pathologists, 2018. Vol. 142, № 5. P. 662–667.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*